Navigation Links
Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe
Date:12/3/2009

s receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Investor Relations Firm Access IR/PR and The Communications Strategy Group Announce Strategic Alliance
2. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
3. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
4. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
5. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
6. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
7. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
8. Access Pharmaceuticals CEO Interviewed on Financial Website
9. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
10. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
11. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/25/2015)... 25, 2015   WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical ... with 20 years of operations in China ... signed an agreement whereby WuXi,s Laboratory Testing Division (LTD) ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... Board: KDUS) announced today financial results for the first,quarter ended ... 2008 were $100,000, compared to,$100,000 for the same period in ... compared to net loss of $558,469 for the same period ... a decrease in general,and administrative expenses of $47,207 and the ...
... Pharmaceutical Services, Inc.,(JOM), a service coordinator that provides ... Ortho Biotech, L.P., was notified May 6,2008, that ... PROCRIT(R) (epoetin alfa) and REMICADE(R) (infliximab) was,stolen while ... in,Kentucky to a specialty distributor. This incident has ...
... MedImmune today announced,that researchers will present eight ... Annual Meeting of the American Thoracic Society, ... Canada. Presentations are designed to showcase,MedImmune,s biologics ... innovative solutions that may one,day help patients ...
Cached Biology Technology:Cadus Reports First Quarter 2008 Results 2Cadus Reports First Quarter 2008 Results 3Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 2Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 3Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 4Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society 2
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... defeat is influenced by his or her stance on ... of the most recent presidential and congressional elections. ... candidates, statements on climate change translated into real votes," ... science at Stanford, who led two new studies ...
... Administration (FDA) has awarded the Georgia Institute of ... Saint Joseph,s Translational Research Institute (SJTRI) a two-year, ... medical devices focused on the special needs of ... Pediatric Device Consortium, which will provide assistance with ...
... October 2011, Singapore A new biotech company has ... (NUS), to provide research tools, targeting the international malaria ... founded by two NUS faculty members: Dr Martin Lear ... Tan from the NUS Department of Microbiology. The company ...
Cached Biology News:Stanford researchers examine impact of 'green politics' on recent national elections 2Stanford researchers examine impact of 'green politics' on recent national elections 3FDA grant launches Atlanta Pediatric Device Consortium 2FDA grant launches Atlanta Pediatric Device Consortium 3FDA grant launches Atlanta Pediatric Device Consortium 4Launch of BioLynx provides a boost for the international malaria research community 2
...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Biology Products: